This report just confirms that we are the world leaders in safe and effective cell elimination technologies. Under the leadership of David M Spencer, we are deploying advances in our original CapspCIDe? technology to develop new therapies that eliminate p-16 expressing senescent and cancer cells. #antiaging #cellandgenetherapy #genetherapy #cancertherapy #innovation #biotechnologies #biotech https://lnkd.in/eEaxqTb
Founder and CEO, SENOTHERAPEUTIX, Inc., a longevity company developing novel senolytic and senomorphic therapeutics that target the fundamental mechanisms of aging.
David M Spencer and I founded Bellicum Pharmaceuticals back in 2004 based on our work together on the cell therapy iCasp9 "safety switch" (which we later named CaspaCIDe?). So after all these years, we are both gratified to see it help resolve severe neurotoxicity, a toxicity seen in many other CD19-targeted CAR T cell therapies, in a patient treated with autologous CD19 CAR T cells. Many experts have doubted that CaspCIDe? would work to resolve neurotoxicity in these patients so its good news for patients that it actually does work as we had thought it would. From the published report in Blood, a journal published by The American Society of Hematology: "Within twelve hours of rimiducid (the small molecule activator of CaspaCIDe?) administration, ICANS grade improved from 3 to 1, with ICE score improving from 0 to 7. ICANS fully resolved four days after rimiducid administration" “We are also encouraged by the anti-leukemic response we observed in this patient even with the use of the iC9 switch.” https://lnkd.in/ewBUMYT #cartcells #immunotherapy #cellulartherapy #toxicity #biotechnews #cartcell